Replies to post #730139 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

no in the JAMA article, the authors said this:

This study has limitations. Since individual patient-level data for the ECPs were not available for this trial

The reason they said that is because individual patient-level data are indeed not present for ECA comparison in GBM trials. The FDA is being incredibly unreasonable.